Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Estimation of Hepatitis C Disease Burden and Budget Impact of Treatment Using Health Economic Modeling.

Infectious disease clinics of North America - 1 Jun 2018

Chhatwal Jagpreet, Chen Qiushi, Aggarwal Rakesh

Abstract excerpt

Oral direct-acting antiviral agents have revolutionized treatment of hepatitis C virus (HCV) infection. Nonetheless, barriers exist to elimination of HCV as a public health threat including low uptake of treatment, limited budget allocations for HCV treatment, and low awareness rates of HCV status among infected people. Mathematical modeling provides a systematic framework to analyze and compare potential...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Cost of Illness
Share to Epidemics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C

Share to Markov Chains

Share to Models, Economic

Share to Models, Theoretical

Share to Public Health

Source

Identifiers

PMID: 29778266
DOI: 10.1016/j.idc.2018.02.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Estimation of Hepatitis C Disease Burden and Budget Impact of Treatment Using Health Economic Modeling.PMID 29778266Read ↗

Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.Semantic proximity Read ↗

Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.Semantic proximity Read ↗

Cost effectiveness of hepatitis C direct acting agents.Semantic proximity Read ↗

Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation.Semantic proximity Read ↗

The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.Semantic proximity Read ↗

The changing burden of hepatitis C virus infection in the United States: model-based predictions.Semantic proximity Read ↗

Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.Semantic proximity Read ↗

Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling studySemantic proximity Read ↗

Cost and cost-effectiveness of Hepatitis C virus self-testing in four settings: an economic evaluationSemantic proximity Read ↗

New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.Semantic proximity Read ↗

Modelling the elimination of hepatitis C virus infection as a public health threatSemantic proximity Read ↗

Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.